Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Tasigna® (nilotinib)
- www.tasigna.com
(For Non U.S. Health Care Professionals Only)
TASIGNA CONTACT
Kim Fox
Novartis Oncology Global Public Relations
office +1 862 778 7692
kim.fox@novartis.com
Amy Vinci
Novartis Oncology Global Public Relations
office +1 862 778 6309
Amy.Vinci@novartis.com
Tasigna® (nilotinib) is a cancer treatment for Philadelphia chromosome positive Chronic Myeloid Leukemia (Ph+ CML) in chronic or accelerated phase in patients resistant to, or experiencing significant toxicity during cancer treatment with, imatinib.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
Tasigna Press Releases
Physician Sound Bites
Tasigna Additional Materials
-
Jun-2010
CML Fact Sheet -
May-2010
Tasigna Fact Sheet -
Nov-2009
ENESTnd Trial Design Visual
